Objectives-To determine whether the TAP2 transporter gene, which lies between HLA-DP and HLA-DQ, is involved in determining susceptibility to systemic lupus erythematosus (SLE). Methods-TAP2 types were determined by ARMS-PCR in 89 white patients with SLE and 156 control subjects. In the present study we have determined the frequences of TAP2 dimorphisms in our SLE patient population and control groups, to determine if TAP2 is involved in genetic predisposition to SLE.
Systemic lupus erythematosus (SLE) is
In the present study we have determined the frequences of TAP2 dimorphisms in our SLE patient population and control groups, to determine if TAP2 is involved in genetic predisposition to SLE.
Materials and methods

SLE AND CONTROL POPULATIONS
The patient population used in the study consisted of 92 white SLE patients, as previously described.5 All patients fulfilled the 1982 ARA revised criteria for SLE. 9 The control population comprised 156 healthy volunteers. DNA 
EXTRACTION
Genomic DNA was extracted from peripheral blood leucocytes as described previously.5 TAP2 TYPING Each TAP2 dimorphism (isoleucine or valine at amino acid (aa) position 379, alanine or threonine at aa positions 565 and 665) was investigated using ARMS-PCR, as previously described.'0 TAP2 alleles were assigned by the haplotype associations of these dimorphic variants: TAP2A = V-379 A-565 T-665, TAP2B = V-379 A-565 A-665, TAP2C = I-379 A-565 T-665, TAP2D = I-379 T-565 T-665 and TAP2E = V-379 T-565 T-665.
DETECTION OF AUTOANTIBODIES
Detection and quantification of antibodies to double-stranded DNA was carried out using a radioimmunoassay kit (Amesham Int). The presence of autoantibodies to four soluble cellular antigens (Ro, La, RNP, Sm) was determined by immunodiffusion and counterimmunoelectrophoresis.
STATISTICAL METHODS
The x2 2 X 2 analysis (with Yates' correction) was used to determine the significance of a frequency difference between two groups (significance level 50/o). The p values obtained were corrected for the number of comparisons made (that is, depending upon the number of variants and the number of groups tested).
When analysing linkage disequilibrium between TAP2 and other loci, delta values (A) were calculated. x2 analysis was used to determine the significance of linkage disequilibrium. Davies , Donn, Hillarby, Grennan, Ollier TAP2A/D and TAP2C/E heterozygotes cannot be distinguished using ARMS-PCR. From the gene frequencies of these alleles, TAP2A/D heterozygotes would be eXpected to occur much more frequently than TAP2C/E heterozygotes. Family studies have confirmed that this is indeed the case (unpublished data). We therefore feel that it is reasonably safe to assume TAP2A/D heterozygosity in such ambiguous cases (of which there were only two in our SLE patient population).
This study clearly indicates that no dimorphism or allele of the TAP2 gene is associated with SLE. In addition, no significant associations were found in any of the clinical/immunological subgroups of SLE that were studied. These data suggest that TAP2 is not involved in determining genetic predisposition to SLE.
We have found no evidence for strong linkage disequilibrium between TAP2 and HLA-DQ/DR. Indeed, no significant linkage was observed in our patient population. We have found TAP2B to be in significant linkage disequilibrium with DR1 (A = 0-056, p = 0.0002) in the control group used in this study. A similar but less marked situation was observed in the SLE group (A = 0-025, p = 0-05) although this was not statistically significant. This apparent discrepancy may be explained by the decreased frequency of DRI in SLE compared with controls in this patient population. Non-significant negative linkage disequilibrium was observed between TAP2B and DR4 (A = -0040, p = 0 03) in our control population, but not in our SLE patient group. TAP2B exhibited non-significant negative linkage disequilibrium with DR3 in SLE patients. These findings agree with those of a previous study in which T-665 (not present in TAP2B) was found to be associated with DR4-DQ8 and DR3-DQ2 haplotypes, while A-665 (present in TAP2B) was associated with DRI-DQ5 haplotypes. 2 The trend towards an increased frequency of TAP2D in SLE patients with circulating antibodies to UlRNP accounts for the increased frequency of threonine at amino acid position 565 in this subgroup. This finding is of particular interest due to the increased frequency of DR4 in this group of patients.5 In the control group used in this study, TAP2D is in linkage disequilibrium with DR4, suggesting that this association is probably not a chance finding. Further studies using larger numbers of patients will help to evaluate the possible association of TAP2C with anti-Ro antibodies and the lack of association of TAP2 with other subgroups of SLE.
This lack of linkage disequilibrium between TAP2 and HLA-DQA/DR indicates that disease-predisposing haplotypes for SLE do not extend as far as TAP2, and our previously reported association of DQA*0501 with SLE5 did not reflect linkage with any TAP2 dimorphism/haplotype. Therefore any associations of HLA-DP alleles with SLE'3 or with specific autoantibody responses" must be independent of other class II (DQ/DR) associations.
